Tests acupuncture to delay Crohn's disease flare-ups
Tests two acupuncture approaches to delay relapse in people with Crohn's disease.
Plain-language title generated from the registry record
Registry title: Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial
Key facts
- Where
- Shanghai, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 16 and 75 years old?
Source: NCT06553053, who can take part
Where in China
- Shanghai Research Institute of Acupuncture and MeridianShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Shanghai Institute of Acupuncture, Moxibustion and Meridian
- Trial code
- NCT06553053
- Record updated
- 13 April 2026
- Original description
The aim of this study was to further improve the clinical efficacy of acupuncture in delaying the clinical recurrence of CD and to explore the efficacy mechanism of acupuncture efficacy enhancement.Read full original descriptionShow less
Acupuncture Reduces Relapse in Patients With Crohn's Disease: a Superiority Trial
The aim of this study was to further improve the clinical efficacy of acupuncture in delaying the clinical recurrence of CD and to explore the efficacy mechanism of acupuncture efficacy enhancement.
Inclusion: patients with clinical diagnosis consistent with CD; aged 16-75; patients in remission (CDAI < 150 and CRP < 5mg/l, or Faecal calprotectin < 50μg/g, or no ulcer under endoscopy); patients with frequent disease recurrences (≥2) in the past years; patients were not taking medication or were only taking one or more of the following drugs: [mesalazine (≤4g/d), prednisone (≤15mg/d), azathioprine (≤1mg/kg/d)] and prednisone and mesalazine were used for at least 1 month, while azathioprine was used for at least 3 months; or those who had poor response or loss of response to biological preparations (anti-TNF-α, IL-12p40, α4β7); those who have never experienced acupuncture; patients signing informed consent.
Exclusion: patients with serious organic diseases; patients who suffer from multiple diseases and need to take other drugs for a long time, and may affect the observation of the efficacy of this trial; severe skin diseases (such as erythema nodosum, pyoderma gangrenosum, etc.), eye diseases (such as iritis, uveitis, etc.), thromboembolic diseases and other serious extraintestinal manifestations; there are serious intestinal fistula, abdominal abscess, intestinal stenosis and obstruction, perianal abscess, gastrointestinal hemorrhage, intestinal perforation and other complications; patients with short bowel syndrome who have undergone abdominal or gastrointestinal surgery in the past half a year; there are skin diseases or defects in the selected area of acupuncture and moxibustion that cannot be performed; patients who are recently pregnant or in pregnancy or lactation; patients diagnosed as psychosis.